Research and Markets: Multiple Sclerosis: KOL Insight

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/67vpwd/multiple) has announced the addition of the "Multiple Sclerosis: KOL Insight" report to their offering.

The past year has seen landmark changes in multiple sclerosis, with the launch of two new novel oral products, Tecfidera (dimethyl fumarate; Biogen Idec) and Aubagio (teriflunomide; Sanofi) joining the first oral MS therapy, Novartis's Gilenya (fingolimod). The arrival of these drugs is expected to revolutionise multiple sclerosis treatment and be a catalyst for unprecedented market growth.

Driven by in-depth interviews with the world's leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Key Features

- This report cuts to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time.

- The unique thought-leader selection matrix identifies the most influential KOLs in MS to deliver the perspectives vital in giving you a competitive edge, enabling informed decision-making and planning.

- Detailed analysis of marketed and pipeline drugs helps you understand the products that will shape the future MS market.

- KOL consensus on the future treatment algorithm offers a window into the future changes in medical evidence and clinical practice.

- Uncovering KOLs' opinions on unmet needs enables you to identify potential commercial opportunities.

Read more from the original source:
Research and Markets: Multiple Sclerosis: KOL Insight